Pfizer said on Thursday it will stop global development and commercialization of its hemophilia gene therapy, Beqvez, citing ...

Pfizer's marstacimab (Hympavzi), an IgG1 monoclonal antibody that helps promote clotting, remains on the market. The drug was ...

Pfizer’s decision to halt further marketing of Beqvez is further sign of the sparse patient interest in gene therapies for ...

Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. | ...

Pfizer said on Thursday it will end global development of its hemophilia gene therapy, Beqvez, citing soft demand from patients and their doctors. Beqvez was approved in the U.S. last year, for the ...

According to multiple media reports on Thursday, Pfizer Inc. (NYSE:PFE) has terminated the global development and ...

Feb 20 (Reuters) - Pfizer (PFE.N), opens new tab said on Thursday it will stop global development and commercialization of its hemophilia gene therapy, Beqvez, citing soft demand from patients and ...

The move comes weeks after Pfizer terminated its partnership with Sangamo Therapeutics for another hemophilia gene therapy.

The hemophilia market is expected to experience significant growth due to advancements in gene therapy, innovative treatments, and an increasing focus on personalized medicine. Rising awareness and ...

Pfizer (PFE) will end global development and commercialization of Beqvez, a gene therapy for hemophilia, Nikkei learned Thursday, after the ...

Pfizer (PFE) discontinues Beqvez hemophilia B therapy developed with Roche (RHHBY) due to low demand, shifting focus to an ...

NEW YORK/TOKYO -- Pfizer will end global development and commercialization of Beqvez, a gene therapy for hemophilia, Nikkei learned Thursday, after the drugmaker dropped its other similar treatment ...